Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review
Tuberculosis (TB), caused by <i>Mycobacterium tuberculosis</i> (Mtb), is a curable airborne disease currently treated using a drug regimen consisting of four drugs. Global TB control has been a persistent challenge for many decades due to the emergence of drug-resistant Mtb strains. The...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/14/5/461 |
| _version_ | 1797534234384007168 |
|---|---|
| author | Klaudia T. Angula Lesetja J. Legoabe Richard M. Beteck |
| author_facet | Klaudia T. Angula Lesetja J. Legoabe Richard M. Beteck |
| author_sort | Klaudia T. Angula |
| collection | DOAJ |
| description | Tuberculosis (TB), caused by <i>Mycobacterium tuberculosis</i> (Mtb), is a curable airborne disease currently treated using a drug regimen consisting of four drugs. Global TB control has been a persistent challenge for many decades due to the emergence of drug-resistant Mtb strains. The duration and complexity of TB treatment are the main issues leading to treatment failures. Other challenges faced by currently deployed TB regimens include drug-drug interactions, miss-matched pharmacokinetics parameters of drugs in a regimen, and lack of activity against slow replicating sub-population. These challenges underpin the continuous search for novel TB drugs and treatment regimens. This review summarizes new TB drugs/drug candidates under development with emphasis on their chemical classes, biological targets, mode of resistance generation, and pharmacokinetic properties. As effective TB treatment requires a combination of drugs, the issue of drug-drug interaction is, therefore, of great concern; herein, we have compiled drug-drug interaction reports, as well as efficacy reports for drug combinations studies involving antitubercular agents in clinical development. |
| first_indexed | 2024-03-10T11:26:47Z |
| format | Article |
| id | doaj.art-5ba1016889da4c9c9b8e7d15d7562513 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T11:26:47Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-5ba1016889da4c9c9b8e7d15d75625132023-11-21T19:33:18ZengMDPI AGPharmaceuticals1424-82472021-05-0114546110.3390/ph14050461Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 ReviewKlaudia T. Angula0Lesetja J. Legoabe1Richard M. Beteck2Centre of Excellence for Pharmaceutical Sciences (Pharmacen), North-West University, Potchefstroom 2520, South AfricaCentre of Excellence for Pharmaceutical Sciences (Pharmacen), North-West University, Potchefstroom 2520, South AfricaCentre of Excellence for Pharmaceutical Sciences (Pharmacen), North-West University, Potchefstroom 2520, South AfricaTuberculosis (TB), caused by <i>Mycobacterium tuberculosis</i> (Mtb), is a curable airborne disease currently treated using a drug regimen consisting of four drugs. Global TB control has been a persistent challenge for many decades due to the emergence of drug-resistant Mtb strains. The duration and complexity of TB treatment are the main issues leading to treatment failures. Other challenges faced by currently deployed TB regimens include drug-drug interactions, miss-matched pharmacokinetics parameters of drugs in a regimen, and lack of activity against slow replicating sub-population. These challenges underpin the continuous search for novel TB drugs and treatment regimens. This review summarizes new TB drugs/drug candidates under development with emphasis on their chemical classes, biological targets, mode of resistance generation, and pharmacokinetic properties. As effective TB treatment requires a combination of drugs, the issue of drug-drug interaction is, therefore, of great concern; herein, we have compiled drug-drug interaction reports, as well as efficacy reports for drug combinations studies involving antitubercular agents in clinical development.https://www.mdpi.com/1424-8247/14/5/461tuberculosisdrug developmentpharmacokineticsfluoroquinolonesdiarylquinolinesnitroimidazoles |
| spellingShingle | Klaudia T. Angula Lesetja J. Legoabe Richard M. Beteck Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review Pharmaceuticals tuberculosis drug development pharmacokinetics fluoroquinolones diarylquinolines nitroimidazoles |
| title | Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review |
| title_full | Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review |
| title_fullStr | Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review |
| title_full_unstemmed | Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review |
| title_short | Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010–2020 Review |
| title_sort | chemical classes presenting novel antituberculosis agents currently in different phases of drug development a 2010 2020 review |
| topic | tuberculosis drug development pharmacokinetics fluoroquinolones diarylquinolines nitroimidazoles |
| url | https://www.mdpi.com/1424-8247/14/5/461 |
| work_keys_str_mv | AT klaudiatangula chemicalclassespresentingnovelantituberculosisagentscurrentlyindifferentphasesofdrugdevelopmenta20102020review AT lesetjajlegoabe chemicalclassespresentingnovelantituberculosisagentscurrentlyindifferentphasesofdrugdevelopmenta20102020review AT richardmbeteck chemicalclassespresentingnovelantituberculosisagentscurrentlyindifferentphasesofdrugdevelopmenta20102020review |